Revolution Medicines
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit difficult growth and survival pathways, with an emphasis on RAS and mTOR signaling. Its portfolio includes RMC-4630, a SHP2 inhibitor, and programs addressing RAS-driven signaling via SOS1 and downstream 4EBP1/mTORC1 pathways. The company pursues a chemistry-based approach that assembles simple building blocks into drug-like, natural product-inspired structures, aiming to produce best-in-class candidates. It operates in collaboration with academic partners, including a licensing arrangement with the University of Illinois to extend its transformative synthesis technology, which underpins its drug discovery platform.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
EQRx
Acquisition in 2023
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.
Warp Drive Bio
Acquisition in 2018
Warp Drive Bio, LLC is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development of genomic technology to discover drugs derived from natural sources. Founded in 2010, the company has created a proprietary genomic search engine that utilizes customized search queries to identify hidden natural products based on their unique genomic signatures. This innovative approach enables researchers to uncover novel drug candidates and analyze their mechanisms of action, facilitating the conversion of genomes into therapeutic drugs. As of October 2018, Warp Drive Bio operates as a subsidiary of REVOLUTION Medicines, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.